SCHEMBL5841584

SCHEMBL5841584

CCc1ccccc1Nc1ccc(NC(=O)C2CC(=O)N(c3ccccc3C(C)C)C2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
ALOX15 P16050 1/20 0.56
ALDH1A1 P00352 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
TP53 P04637 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
POLB P06746 3/20 0.49
ATM Q13315 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842343 0.93 MEN1 (0.54) MEN1KMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL5844184 0.91 ALOX15 (0.61) MEN1KMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL5841845 0.91 MEN1 (0.53) MEN1KMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL5841925 0.91 ALOX15 (0.55) MEN1KMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL5842611 0.89 MAPT (0.62) MEN1KMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL5843598 0.87 ALOX15 (0.67) MEN1KMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL5842613 0.82 MAPT (0.56) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL5841574 0.81 ALOX15 (0.59) MEN1KMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL5842322 0.80 ALDH1A1 (0.57) MEN1KMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL5842420 0.80 MAPT (0.54) ALDH1A1SMN1; SMN2MAPTNPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100534990-C Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 CN claimed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US claimed
CN-1610678-A Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2005-04-27 CN claimed
CN-100534990-C Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 CN disclosed
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed
CN-1610678-A Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2005-04-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R MEN1 3619/4885KMT2A 3347/4885ALOX15 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.